Novocure’s cancer therapy fails to meet main goal in late-stage trial

,

Novocure’s cancer therapy fails to meet main goal in late-stage trial

Aug 28 (Reuters) – Novocure (NVCR.O) said on Monday its therapy failed in a late-stage trial to meet the main goal of improving survival rates in patients with a type of ovarian cancer.

Novocure’s therapy, which is used with certain chemotherapies and immunotherapies, creates electric fields that exert physical forces to kill cancer cells.

The combination therapy showed an overall survival rate of 12.2 months compared to 11.9 months in patients who were treated only with paclitaxel – the chemotherapy it was combined with.

Reporting by Sriparna Roy in Bengaluru; Editing by Nivedita Bhattacharjee

Source: Reuters

/by
You might also like
Johnson & JohnsonJohnson & Johnson’s blood cancer therapy gets U.S. FDA approval
BioNTechCash-rich BioNTech broadens scope as COVID shot sales slide
pharmaceuticalsDrugmakers go under the skin, skirting early US Medicare price negotiations
neuropathic painLexicon’s AAK1 inhibitor disappoints in Phase II postherpetic neuralgia study
FDAAbbVie, Genmab score FDA nod for DLBCL as blood cancer space heats up
Johnson & Johnson, baby powderJ&J can contest evidence linking its talc to cancer, US judge rules
Eliquis, Bristol Myers SquibbBristol Myers Squibb 2023: Changing hands
AstraZenecaAstraZeneca shares fall as lung cancer drug trial data abstract disappoints